Citadel Advisors
LTRN icon

Citadel Advisors’s Lantern Pharma LTRN Stock Holding History

Citadel Advisors’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,300
Closed -$37.3K – 13687
2025
Q4 		$37.3K Sell
12,300
-6,100
-33% -$22.7K ﹤0.01% 12147
2025
Q3 		$80K Buy
18,400
+2,000
+12% +$8.35K ﹤0.01% 11971
2025
Q2 		$51.8K Sell
16,400
-700
-4% -$2.36K ﹤0.01% 11749
2025
Q1 		$60.5K Buy
17,100
+12,500
+272% +$51.9K ﹤0.01% 12102
2024
Q4 		$14.7K Sell
4,600
-35,200
-88% -$121K ﹤0.01% 13395
2024
Q3 		$146K Sell
39,800
-3,000
-7% -$12.4K ﹤0.01% 10596
2024
Q2 		$200K Buy
42,800
+22,900
+115% +$138K ﹤0.01% 9948
2024
Q1 		$175K Buy
19,900
+19,700
+9,850% +$105K ﹤0.01% 10539
2023
Q4 		$856 Sell
200
-2,000
-91% -$7.05K ﹤0.01% 13925
2023
Q3 		$7.5K Buy
2,200
+2,000
+1,000% +$9.08K ﹤0.01% 13254
2023
Q2 		$1.13K Sell
200
-7,300
-97% -$37.7K ﹤0.01% 13982
2023
Q1 		$36.2K Buy
7,500
+700
+10% +$3.68K ﹤0.01% 12550
2022
Q4 		$41.1K Sell
6,800
-4,500
-40% -$22.5K ﹤0.01% 12377
2022
Q3 		$54K Buy
+11,300
New +$60.7K ﹤0.01% 11569

Other funds holding LTRN

EAM
Empery Asset Management New York $86.5M AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Citadel Advisors's LTRN Position: Q2 2026 in Review

Citadel Advisors opened a new position in Lantern Pharma (LTRN) in Q2 2026: 47,895 shares worth $200K. The stake represents ﹤0.01% of the portfolio and ranks #12071 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LTRN as recently as Q4 2025.

Citadel Advisors first reported a position in LTRN in Q1 2021 and has held it in 12 quarters since. The position peaked at $203K in Q1 2021. 39 funds tracked by Wall St. Rank hold LTRN as of Q2 2026.

  • Citadel Advisors held 47,895 shares of Lantern Pharma worth $200K as of Q2 2026.
  • Lantern Pharma was a new Citadel Advisors position in Q2 2026.
  • Lantern Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12071 holding.
  • Citadel Advisors first reported a position in Lantern Pharma in Q1 2021 and has held it in 12 quarters since.
  • Citadel Advisors's Lantern Pharma position peaked at $203K in Q1 2021.
  • 39 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.